Mr. Stanley Sack reports

AURORA ADVANCES GLOBAL MEDICAL GROWTH STRATEGY WITH PORTFOLIO EXPANSION IN AUSTRALIA & NEW ZEALAND

Aurora Cannabis Inc. has expanded its Aurora medical portfolio in Australia and New Zealand, delivering patients and prescribers enhanced choice, reliable quality and easier access to science-backed products. The expansion underscores the company's continuing dedication to meeting the unique needs of patients and health care professionals in the region, reflecting Aurora's strategic focus on long-term global growth.

The expansion in New Zealand this month includes two new THC (tetrahydrocannabinol) flower products -- Big Wave, Night Ride as well as the balanced strain, Half Moon, coming soon in Q1 fiscal 2027. The brand will also debut four new resin cartridges in Australia this month, including Chemango Kush, Cosmic Cream, Lunar Express and Soul Train Haze.

"With Australia being one of our largest international medical cannabis market, both Australia and New Zealand remain a top priority for Aurora, and we are deeply committed to our continued investment across the region," said Stanley Sack, interim managing director of MedReleaf Australia. "As patient needs evolve, so does our responsibility to deliver high-quality, diversified product formats that support prescribers in delivering better care. Our focus on quality and reliable supply reflects our dedication to ensuring patients have meaningful access to the products they depend on."

Each new product is derived from Aurora's proprietary genetics and manufactured at the company's leading EU-GMP- (European Union good manufacturing practice) and TGA-GMP-certified (Therapeutic Goods Administration good manufacturing practice) facilities in Canada, ensuring the highest standards of quality and safety.

New Zealand launches:

• Big Wave -- flower, hybrid, THC 26 per cent, CBD (cannabidiol) less than 1 per cent;
• Night Ride -- flower, indica, THC 29 per cent, CBD less than 1 per cent;
• Half Moon -- flower, hybrid, THC 9 per cent, CBD 13 per cent.

Australia launches:

• Chemango Kush -- resin cartridge, indica, THC 780 milligrams per gram, CBD less than 10 mg/g;
• Cosmic Cream -- resin cartridge, indica, THC 780 mg/g, CBD less than 10 mg/g;
• Lunar Express -- resin cartridge, indica, THC 780 mg/g, CBD less than 10 mg/g;
• Soul Train Haze -- resin cartridge, sativa, THC 780 mg/g, CBD less than 10 mg/g;

Aurora remains a trusted choice for prescribers and patients around the globe. With a broad portfolio of high-quality medical cannabis, proven regulatory expertise and strong leadership across a dozen markets, Aurora continues to raise the bar for supporting patient care.

About Aurora Cannabis Inc.

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora, MedReleaf, Pedanios, IndiMed, San Raf, Tasty's and Whistler Medical Marijuana Co. The company also holds a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of opening the world to cannabis.

Aurora's common shares trade on the Nasdaq Stock Market and the Toronto Stock Exchange under the symbol ACB.

We seek Safe Harbor.